Prostacyclin Pathway Targeted Therapy Therapeutics
1. Uptravi patent expiration
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...
UPTRAVI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(8 months from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9284280 (Pediatric) | ACTELION | Use Of Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide |
Dec, 2030
(4 years from now) | |
|
US9173881 (Pediatric) | ACTELION | Therapeutic Compositions Containing Macitentan |
Feb, 2030
(3 years from now) | |
|
US8791122 (Pediatric) | ACTELION | Form-I Crystal Of 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide And Method For Producing The Same |
Feb, 2031
(4 years from now) | |
|
US7205302 (Pediatric) | ACTELION | Heterocyclic Compound Derivatives And Medicines |
Apr, 2027
(1 year, 2 months from now) | |
|
US10821108 (Pediatric) | ACTELION | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)Acetamide |
Jun, 2037
(11 years from now) | |
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(3 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(4 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(10 years from now) | |
|
US10828298 (Pediatric) | ACTELION | Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy]-N-(Methylsulfonyl)Acetamide |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Dosage: TABLET; POWDER
How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage
UPTRAVI family patents
